Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [177Lu]Lu-PSMA-617
In recent years, radiolabeled tracers targeting prostate-specific membrane antigen (PSMA) have had a tremendous impact on prostate cancer management. Here, we report on the formation of radioactive impurities formed during the clinical production of 177Lu-labeled PSMA-617. We provide compelling evid...
Gespeichert in:
Veröffentlicht in: | Journal of medicinal chemistry 2021-04, Vol.64 (8), p.4960-4971 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 4971 |
---|---|
container_issue | 8 |
container_start_page | 4960 |
container_title | Journal of medicinal chemistry |
container_volume | 64 |
creator | Martin, Sebastian Tönnesmann, Roswitha Hierlmeier, Ina Maus, Stephan Rosar, Florian Ruf, Juri Holland, Jason P Ezziddin, Samer Bartholomä, Mark D |
description | In recent years, radiolabeled tracers targeting prostate-specific membrane antigen (PSMA) have had a tremendous impact on prostate cancer management. Here, we report on the formation of radioactive impurities formed during the clinical production of 177Lu-labeled PSMA-617. We provide compelling evidence that these impurities are the result of a spontaneous, thermally mediated condensation reaction of the Glu-CO-Lys moiety resulting in the formation of three different five-membered ring systems. Density functional theory (DFT) calculations show that the condensation and cyclization of the Glu-CO-Lys moiety is thermodynamically spontaneous. In cell experiments, no affinity of these cyclized compounds toward PSMA was observed. HPLC analyses of urine samples from patient studies showed rapid renal excretion of these radioactive cyclized species. Radiolabeling conditions were identified that significantly reduced the formation of cyclized side products yielding 177Lu-labeled PSMA-617 in high radiochemical yield and purity in concordance with current good manufacturing practice (cGMP) requirements. |
doi_str_mv | 10.1021/acs.jmedchem.1c00045 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2510247580</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2510247580</sourcerecordid><originalsourceid>FETCH-LOGICAL-a394t-1a440a0e114f7d0af9b3ed07f09cf727930a8381aaa7d49fc74c369026a4005b3</originalsourceid><addsrcrecordid>eNp9kE1PGzEQhq2qqKTAP6iQjxy6Yfyx690jihqIlKpIgRNCq4k_GqNkN9jrQ_j1OE3g2NNIM887Yz-E_GAwZsDZNeo4ftlYo1d2M2YaAGT5hYxYyaGQNcivZATAecErLk7J9xhfMiIYF9_IqRA1rwSHERlmxnaDd17j4PvuJ52sMKAebPBvxw52hi7SdhtsjLlBe0cX3lh6H3qT9BDptA_5HdSk4Lu_dFhZuth1uUQf9_ATU2qenuepuF_8vikqps7JicN1tBfHekYep78eJnfF_M_tbHIzL1A0cigYSgkIljHplAF0zVJYA8pBo53iqhGAtagZIiojG6eV1KJqgFcoAcqlOCNXh73b0L8mG4d246O26zV2tk-x5WU2KVVZQ0blAdWhjzFY126D32DYtQzave82-24_fLdH3zl2ebyQlnn2GfoQnAE4AP_ifQpd_vD_d74Dh4iOow</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2510247580</pqid></control><display><type>article</type><title>Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [177Lu]Lu-PSMA-617</title><source>American Chemical Society Journals</source><creator>Martin, Sebastian ; Tönnesmann, Roswitha ; Hierlmeier, Ina ; Maus, Stephan ; Rosar, Florian ; Ruf, Juri ; Holland, Jason P ; Ezziddin, Samer ; Bartholomä, Mark D</creator><creatorcontrib>Martin, Sebastian ; Tönnesmann, Roswitha ; Hierlmeier, Ina ; Maus, Stephan ; Rosar, Florian ; Ruf, Juri ; Holland, Jason P ; Ezziddin, Samer ; Bartholomä, Mark D</creatorcontrib><description>In recent years, radiolabeled tracers targeting prostate-specific membrane antigen (PSMA) have had a tremendous impact on prostate cancer management. Here, we report on the formation of radioactive impurities formed during the clinical production of 177Lu-labeled PSMA-617. We provide compelling evidence that these impurities are the result of a spontaneous, thermally mediated condensation reaction of the Glu-CO-Lys moiety resulting in the formation of three different five-membered ring systems. Density functional theory (DFT) calculations show that the condensation and cyclization of the Glu-CO-Lys moiety is thermodynamically spontaneous. In cell experiments, no affinity of these cyclized compounds toward PSMA was observed. HPLC analyses of urine samples from patient studies showed rapid renal excretion of these radioactive cyclized species. Radiolabeling conditions were identified that significantly reduced the formation of cyclized side products yielding 177Lu-labeled PSMA-617 in high radiochemical yield and purity in concordance with current good manufacturing practice (cGMP) requirements.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/acs.jmedchem.1c00045</identifier><identifier>PMID: 33826320</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><ispartof>Journal of medicinal chemistry, 2021-04, Vol.64 (8), p.4960-4971</ispartof><rights>2021 American Chemical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a394t-1a440a0e114f7d0af9b3ed07f09cf727930a8381aaa7d49fc74c369026a4005b3</citedby><cites>FETCH-LOGICAL-a394t-1a440a0e114f7d0af9b3ed07f09cf727930a8381aaa7d49fc74c369026a4005b3</cites><orcidid>0000-0002-0066-219X ; 0000-0002-0361-2833</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00045$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00045$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,780,784,2765,27076,27924,27925,56738,56788</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33826320$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martin, Sebastian</creatorcontrib><creatorcontrib>Tönnesmann, Roswitha</creatorcontrib><creatorcontrib>Hierlmeier, Ina</creatorcontrib><creatorcontrib>Maus, Stephan</creatorcontrib><creatorcontrib>Rosar, Florian</creatorcontrib><creatorcontrib>Ruf, Juri</creatorcontrib><creatorcontrib>Holland, Jason P</creatorcontrib><creatorcontrib>Ezziddin, Samer</creatorcontrib><creatorcontrib>Bartholomä, Mark D</creatorcontrib><title>Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [177Lu]Lu-PSMA-617</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>In recent years, radiolabeled tracers targeting prostate-specific membrane antigen (PSMA) have had a tremendous impact on prostate cancer management. Here, we report on the formation of radioactive impurities formed during the clinical production of 177Lu-labeled PSMA-617. We provide compelling evidence that these impurities are the result of a spontaneous, thermally mediated condensation reaction of the Glu-CO-Lys moiety resulting in the formation of three different five-membered ring systems. Density functional theory (DFT) calculations show that the condensation and cyclization of the Glu-CO-Lys moiety is thermodynamically spontaneous. In cell experiments, no affinity of these cyclized compounds toward PSMA was observed. HPLC analyses of urine samples from patient studies showed rapid renal excretion of these radioactive cyclized species. Radiolabeling conditions were identified that significantly reduced the formation of cyclized side products yielding 177Lu-labeled PSMA-617 in high radiochemical yield and purity in concordance with current good manufacturing practice (cGMP) requirements.</description><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kE1PGzEQhq2qqKTAP6iQjxy6Yfyx690jihqIlKpIgRNCq4k_GqNkN9jrQ_j1OE3g2NNIM887Yz-E_GAwZsDZNeo4ftlYo1d2M2YaAGT5hYxYyaGQNcivZATAecErLk7J9xhfMiIYF9_IqRA1rwSHERlmxnaDd17j4PvuJ52sMKAebPBvxw52hi7SdhtsjLlBe0cX3lh6H3qT9BDptA_5HdSk4Lu_dFhZuth1uUQf9_ATU2qenuepuF_8vikqps7JicN1tBfHekYep78eJnfF_M_tbHIzL1A0cigYSgkIljHplAF0zVJYA8pBo53iqhGAtagZIiojG6eV1KJqgFcoAcqlOCNXh73b0L8mG4d246O26zV2tk-x5WU2KVVZQ0blAdWhjzFY126D32DYtQzave82-24_fLdH3zl2ebyQlnn2GfoQnAE4AP_ifQpd_vD_d74Dh4iOow</recordid><startdate>20210422</startdate><enddate>20210422</enddate><creator>Martin, Sebastian</creator><creator>Tönnesmann, Roswitha</creator><creator>Hierlmeier, Ina</creator><creator>Maus, Stephan</creator><creator>Rosar, Florian</creator><creator>Ruf, Juri</creator><creator>Holland, Jason P</creator><creator>Ezziddin, Samer</creator><creator>Bartholomä, Mark D</creator><general>American Chemical Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0066-219X</orcidid><orcidid>https://orcid.org/0000-0002-0361-2833</orcidid></search><sort><creationdate>20210422</creationdate><title>Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [177Lu]Lu-PSMA-617</title><author>Martin, Sebastian ; Tönnesmann, Roswitha ; Hierlmeier, Ina ; Maus, Stephan ; Rosar, Florian ; Ruf, Juri ; Holland, Jason P ; Ezziddin, Samer ; Bartholomä, Mark D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a394t-1a440a0e114f7d0af9b3ed07f09cf727930a8381aaa7d49fc74c369026a4005b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martin, Sebastian</creatorcontrib><creatorcontrib>Tönnesmann, Roswitha</creatorcontrib><creatorcontrib>Hierlmeier, Ina</creatorcontrib><creatorcontrib>Maus, Stephan</creatorcontrib><creatorcontrib>Rosar, Florian</creatorcontrib><creatorcontrib>Ruf, Juri</creatorcontrib><creatorcontrib>Holland, Jason P</creatorcontrib><creatorcontrib>Ezziddin, Samer</creatorcontrib><creatorcontrib>Bartholomä, Mark D</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martin, Sebastian</au><au>Tönnesmann, Roswitha</au><au>Hierlmeier, Ina</au><au>Maus, Stephan</au><au>Rosar, Florian</au><au>Ruf, Juri</au><au>Holland, Jason P</au><au>Ezziddin, Samer</au><au>Bartholomä, Mark D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [177Lu]Lu-PSMA-617</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2021-04-22</date><risdate>2021</risdate><volume>64</volume><issue>8</issue><spage>4960</spage><epage>4971</epage><pages>4960-4971</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><abstract>In recent years, radiolabeled tracers targeting prostate-specific membrane antigen (PSMA) have had a tremendous impact on prostate cancer management. Here, we report on the formation of radioactive impurities formed during the clinical production of 177Lu-labeled PSMA-617. We provide compelling evidence that these impurities are the result of a spontaneous, thermally mediated condensation reaction of the Glu-CO-Lys moiety resulting in the formation of three different five-membered ring systems. Density functional theory (DFT) calculations show that the condensation and cyclization of the Glu-CO-Lys moiety is thermodynamically spontaneous. In cell experiments, no affinity of these cyclized compounds toward PSMA was observed. HPLC analyses of urine samples from patient studies showed rapid renal excretion of these radioactive cyclized species. Radiolabeling conditions were identified that significantly reduced the formation of cyclized side products yielding 177Lu-labeled PSMA-617 in high radiochemical yield and purity in concordance with current good manufacturing practice (cGMP) requirements.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>33826320</pmid><doi>10.1021/acs.jmedchem.1c00045</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-0066-219X</orcidid><orcidid>https://orcid.org/0000-0002-0361-2833</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-2623 |
ispartof | Journal of medicinal chemistry, 2021-04, Vol.64 (8), p.4960-4971 |
issn | 0022-2623 1520-4804 |
language | eng |
recordid | cdi_proquest_miscellaneous_2510247580 |
source | American Chemical Society Journals |
title | Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [177Lu]Lu-PSMA-617 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T18%3A14%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identification,%20Characterization,%20and%20Suppression%20of%20Side%20Products%20Formed%20during%20the%20Synthesis%20of%20%5B177Lu%5DLu-PSMA-617&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Martin,%20Sebastian&rft.date=2021-04-22&rft.volume=64&rft.issue=8&rft.spage=4960&rft.epage=4971&rft.pages=4960-4971&rft.issn=0022-2623&rft.eissn=1520-4804&rft_id=info:doi/10.1021/acs.jmedchem.1c00045&rft_dat=%3Cproquest_cross%3E2510247580%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2510247580&rft_id=info:pmid/33826320&rfr_iscdi=true |